Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

The withholding of test results as a means of assessing the effectiveness of treatment in test-positive persons.

Weiss NS.

J Clin Epidemiol. 2013 Apr;66(4):355-8. doi: 10.1016/j.jclinepi.2012.07.011.

PMID:
22981247
2.

[Randomized clinical trials: variants, randomization methods, analysis, ethical issues and regulations].

Lazcano-Ponce E, Salazar-Martínez E, Gutiérrez-Castrellón P, Angeles-Llerenas A, Hernández-Garduño A, Viramontes JL.

Salud Publica Mex. 2004 Nov-Dec;46(6):559-84. Review. Spanish. No abstract available.

PMID:
15624861
3.

Ethical conduct of radiology research with human participants.

Burger I, Kass N.

J Am Coll Radiol. 2006 Dec;3(12):932-9. Review.

PMID:
17412204
4.

Various randomized designs can be used to evaluate medical tests.

Lijmer JG, Bossuyt PM.

J Clin Epidemiol. 2009 Apr;62(4):364-73. doi: 10.1016/j.jclinepi.2008.06.017.

PMID:
18945590
5.
6.

Withholding information from study participants in clinical trials: ethical considerations.

Dosik M.

J Clin Oncol. 2005 Jul 1;23(19):4468-9; author reply 4469. No abstract available.

PMID:
15994162
7.

Clinical trial design issues: at least 10 things you should look for in clinical trials.

Glasser SP, Howard G.

J Clin Pharmacol. 2006 Oct;46(10):1106-15. Review.

PMID:
16988199
8.

Ethical issues arising when interim data in clinical trials is restricted to independent data monitoring committees.

Wells RJ, Gartside PS, McHenry CL.

IRB. 2000 Jan;22(1):7-11. No abstract available.

PMID:
12546010
9.

Commentary: Randomized trials of controversial social interventions: slow progress in 50 years.

Goldacre B.

Int J Epidemiol. 2015 Feb;44(1):19-22. doi: 10.1093/ije/dyv005. No abstract available.

10.

A free-market approach to clinical data gathering is more ethical.

Keane M.

Am J Bioeth. 2013;13(9):19-21. doi: 10.1080/15265161.2013.814732. No abstract available.

PMID:
23952825
11.

Issues in the use of stepped wedge cluster and alternative designs in the case of pandemics.

van der Tweel I, van der Graaf R.

Am J Bioeth. 2013;13(9):23-4. doi: 10.1080/15265161.2013.813603. No abstract available.

PMID:
23952827
12.

Placebo controls: scientific and ethical issues.

Kowalski CJ.

Am J Bioeth. 2002 Spring;2(2):33-4. No abstract available.

PMID:
12189073
13.

Cluster randomized controlled trials in primary care: an introduction.

Murphy AW, Esterman A, Pilotto LS.

Eur J Gen Pract. 2006;12(2):70-3.

PMID:
16945880
14.

Costs and effectiveness of substance abuse treatments for homeless persons.

Schumacher JE, Mennemeyer ST, Milby JB, Wallace D, Nolan K.

J Ment Health Policy Econ. 2002 Mar;5(1):33-42.

PMID:
12529568
15.

Composite outcomes can distort the nature and magnitude of treatment benefits in clinical trials.

Ferreira-Gonzalez I, Permanyer-Miralda G, Busse JW, Devereaux PJ, Guyatt GH, Alonso-Coello P, Montori VM.

Ann Intern Med. 2009 Apr 21;150(8):566-7. No abstract available.

PMID:
19380859
16.

Clinical research should not be permitted to escape the ethical orbit of clinical care.

Steinberg D.

Am J Bioeth. 2002 Spring;2(2):27-8. No abstract available.

PMID:
12189069
17.

Dissemination to research subjects: operationalizing investigator accountability.

Zlotnik Shaul R, Reid L, Essue B, Gibson J, Marzinotto V, Daneman D.

Account Res. 2005 Jan-Mar;12(1):1-16.

PMID:
16021788
18.

Subject indifference and the justification of placebo-controlled trials.

Veatch RM.

Am J Bioeth. 2002 Spring;2(2):12-3. No abstract available.

PMID:
12189061
19.
20.
Items per page

Supplemental Content

Support Center